| Literature DB >> 35993903 |
Kenji Inafuku1, Akimasa Sekine2, Hiromasa Arai1, Eri Hagiwara2, Shigeru Komatsu2, Tae Iwasawa3, Toshihiro Misumi4, Noritake Kikunishi1, Michihiko Tajiri1, Koji Okudela5, Yasushi Rino6, Takashi Ogura2.
Abstract
OBJECTIVES: Pleuroparenchymal fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by pleural-parenchymal involvement, predominantly in the upper lobes. Unilateral upper lung field pulmonary fibrosis (upper-PF) that is radiologically consistent with PPFE reportedly develops after lung cancer surgery in the operated side and presents many clinical characteristics in common with PPFE. However, the incidence and perioperative associated factors remain unclear.Entities:
Keywords: Late complication; Pleural effusion; Pleuroparenchymal fibroelastosis; Surgery; Unilateral
Mesh:
Year: 2022 PMID: 35993903 PMCID: PMC9487195 DOI: 10.1093/icvts/ivac223
Source DB: PubMed Journal: Interact Cardiovasc Thorac Surg ISSN: 1569-9285
Patient characteristics
| Characteristics | All cases | With unilateral upper-PF | Without unilateral upper-PF |
|
|---|---|---|---|---|
| (n = 587) | (n = 25) | (n = 562) | ||
| Age (years) | ||||
| Median (range) | 69 (25–86) | 73 (55–85) | 69 (25–86) | 0.035 |
| < 70, n (%) | 307 (52.2) | 8 (32.0) | 299 (53.2) | 0.042 |
| ≥ 70 | 280 (47.7) | 17 (68.0) | 263 (46.8) | |
| Sex, n (%) | ||||
| Male | 331 (56.3) | 21 (84.0) | 310 (55.1) | 0.004 |
| Female | 256 (43.6) | 4 (16.0) | 252 (44.8) | |
| Smoking history, n (%) | ||||
| Yes | 356 (60.6) | 19 (76.0) | 337 (60.0) | 0.143 |
| No | 231 (39.4) | 6 (24.0) | 225 (40.0) | |
| BMI (kg/m2) | ||||
| Median (range) | 22.2 (15.2–43.9) | 20.3 (16.0–26.1) | 22.3 (15.2–43.9) | 0.014 |
| %VC (%) | ||||
| Median (range) | 104.9 (51.3–169.8) | 100.7 (72.4–129.5) | 105.1 (51.3–169.8) | 0.056 |
| ≥ 80, n (%) | 561 (95.6) | 22 (88.0) | 539 (95.9) | 0.093 |
| < 80 | 26 (4.4) | 3 (12.0) | 23 (4.1) | |
| FEV1.0% (%) | ||||
| Median (range) | 73.1 (29.0–100.0) | 74.1 (45.6–99.4) | 73.0 (29.0–100.0) | 0.325 |
| ≥ 70, n (%) | 376 (64.1) | 15 (60.0) | 361 (64.2) | 0.674 |
| < 70 | 211 (35.9) | 10 (40.0) | 201 (65.8) | |
| Operative approach, n (%) | ||||
| VATS | 554 (94.3) | 23 (92.0) | 531 (94.5) | 0.645 |
| Open thoracotomy | 33 (5.6) | 2 (8.0) | 31 (5.5) | |
| Operative procedure, n (%) | ||||
| Lobar resection | 434 (73.9) | 23 (92.0) | 411 (73.1) | 0.036 |
| Sublobar resection | 153 (26.0) | 2 (8.0) | 151 (26.9) | |
| Use of PGA sheet and fibrin glue | ||||
| Yes | 542 (92.3) | 25 (100) | 517 (92.0) | 0.246 |
| No | 45 (7.7) | 0 (0) | 45 (8.0) | |
| Pulmonary apical cap, n (%) | ||||
| Absent | 343 (58.4) | 4 (16.0) | 339 (60.3) | < 0.001 |
| Present | 244 (41.6) | 21 (84.0) | 223 (39.7) | |
| Adjuvant chemotherapy | ||||
| Yes | 47 (80.0) | 1 | 46 (8.2) | 0.712 |
| No | 540 (20.0) | 24 (96.0) | 516 (91.8) | |
Uracil-tegafur was administered orally.
BMI: body mass index; FEV1.0%: % forced expiratory volume in 1 s; lobar resection: lobectomy or bilobectomy; %VC: % vital capacity; PGA: polyglycolic acid; sublobar resection: wedge resection or segmentectomy; upper-PF: upper lung field pulmonary fibrosis; VATS: video assisted thoracoscopic surgery.
Operative procedures of the patient with unilateral upper-PF
| Operative procedures | n |
|---|---|
| Lobar resection | 23 |
| Lobectomy | 19 |
| Right upper lobectomy | 4 |
| Right middle lobectomy | 1 |
| Right lower lobectomy | 8 |
| Left upper lobectomy | 5 |
| Left lower lobectomy | 1 |
| Bilobectomy | 4 |
| Right middle and lower lobectomy | 2 |
| Right upper and middle lobectomy | 2 |
| Sublobar resection | 2 |
| Left upper division segmentectomy | 1 |
| Left lower lobe wedge resection | 1 |
upper-PF: upper lung field pulmonary fibrosis.
Figure 1:(A–E) Cumulative incidence curves of unilateral upper-PF after lung cancer surgery. upper-PF: upper lung field pulmonary fibrosis; VC: vital capacity.
Postoperative pleural effusion 6 months after surgery
| Pleural effusion | With unilateral upper-PF | Without unilateral upper-PF |
|
|---|---|---|---|
| All lung cancer surgery (n = 587) | |||
| Present | 24 (96.0) | 136 (24.2) | < 0.001 |
| Absent | 1 (4.0) | 426 (75.8) | |
| Lobar resection (n = 434) | |||
| Present | 22 (95.7) | 111 (27.0) | < 0.001 |
| Absent | 1 (4.3) | 300 (73.0) | |
| Sublobar resection (n = 153) | |||
| Present | 2 (100) | 8 (5.3) | 0.0039 |
| Absent | 0 (0) | 143 (94.7) |
lobar resection: lobectomy or bilobectomy; sublobar resection: wedge resection or segmentectomy; upper-PF: upper lung field pulmonary fibrosis.
Clinical and radiological courses of 25 patients with unilateral upper-PF
| Median interval time from surgery to diagnosis of upper-PF (range) | 36.3 months |
|---|---|
| (4.8–121.8) | |
| Aberrant air, n (%) | |
| Present | 17 (68.0) |
| Absent | 8 (32.0) |
| Radiological findings of upper-PF, n (%) | |
| Cystic change | 20 (80.0) |
| Only fibrosis lesion | 5 (20.0) |
| Subsequent complication related to upper-PF, n (%) | |
| Present | 18 (72.0) |
| Complications (a cumulative total of) | |
| Progressive respiratory distress | 9 |
| Progressive body weight loss | 9 |
| Pneumonia | 6 |
| Pulmonary aspergillus | 4 |
| Nontuberculous mycobacterium infection | 1 |
| Absent | 5 (20.0) |
| Unknown | 2 (8.0) |
| Unilateral thoracic deformity, n (%) | |
| Present | 21 (84.0) |
| Absent | 4 (16.0) |
| Prognosis, n (%) | |
| Alive | 19 (76.0) |
| Dead | 6 (24.0) |
| Causes of death | |
| Pulmonary aspergillus | 2 |
| Hypercapnic chronic respiratory failure | 2 |
| Pneumonia | 2 |
upper-PF: upper lung field pulmonary fibrosis.
Univariable and multivariable analyses for perioperative associated factors for unilateral upper-PF
| Variables | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| SHR | 95% CI |
| SHR | 95% CI |
| |
| Age (≥ 70) | 2.50 | 1.09–5.76 | 0.031 | 2.07 | 0.845–5.02 | 0.11 |
| Sex (male) | 4.11 | 1.41–12.00 | 0.0096 | 4.25 | 1.40–12.84 | 0.010 |
| Smoking history (yes) | 2.13 | 0.85–5.32 | 0.11 | |||
| BMI | 0.85 | 0.75–0.96 | 0.0078 | 0.89 | 0.76–1.05 | 0.18 |
| %VC (< 80%) | 3.39 | 1.02–11.26 | 0.047 | 3.56 | 1.02–2.46 | 0.047 |
| FEV1.0% (< 70%) | 1.25 | 0.33–2.79 | 0.57 | |||
| Operative approach (open thoracotomy) | 1.37 | 0.33–5.65 | 0.67 | |||
| Operative procedure (lobar resection) | 4.20 | 1.01–17.58 | 0.049 | 4.31 | 1.08–17.15 | 0.038 |
| Use of PGA sheet and fibrin glue | N/E | |||||
| Pulmonary apical cap (presence) | 7.71 | 2.64–22.52 | 0.00019 | 6.47 | 1.87–22.30 | 0.0032 |
| Adjuvant chemotherapy (yes) | 0.64 | 0.08-4.81 | 0.66 | |||
upper-PF: upper lung field pulmonary fibrosis; BMI: body mass index; CI: confidence interval; FEV1.0%: % forced expiratory volume in 1 s; lobar resection: lobectomy or bilobectomy; N/E: not evaluable because no patients developed upper lung field pulmonary fibrosis without the use of PGA sheet and fibrin glue; %VC: % vital capacity; PGA: polyglycolic acid; SHR: subdistribution hazard ratio.
Cumulative incidence of unilateral upper-PF according to perioperative characteristics
| Cumulative incidence (95% C.I.) | |||
|---|---|---|---|
| Perioperative characteristics | 3-year | 5-year | 10-year |
| Entire population | 2.3% (1.3–3.8) | 3.3% (2.0–5.0) | 5.3% (3.4–7.9) |
| Operative procedure | |||
| Lobar resection | 3.1% (1.7–5.1) | 4.1% (2.5–6.3) | 6.3% (3.9–.4) |
| Sublobar resection | 0.0% (0.0–0.0) | 0.8% (0.1–4.2) | 2.6% (0.4–8.7) |
| Sex | |||
| Male | 2.8% (1.4–5.1) | 4.5% (2.6–7.3) | 8.0% (4.9–12.2) |
| Female | 1.6% (0.5–3.8) | 1.6% (0.5–3.8) | 1.6% (0.5–3.8) |
| Apical cap | |||
| Present | 4.6% (2.4–7.8) | 6.5% (3.8–10.2) | 10.3% (6.3–15.4) |
| Absent | 0.6% (0.1–2.1) | 1.0% (0.3–2.6) | 1.8% (0.5–4.7) |
| %VC | |||
| < 80% | 8.8% (1.4–25.0) | 14.5% (3.3–33.5) | 14.5% (3.3–33.5) |
| ≥ 80% | 2.0% (1.1–3.5%) | 2.8% (1.6–4.5%) | 4.9% (3–7.5) |
On the operated side.
CI: confidence interval; lobar resection: lobectomy or bilobectomy; sublobar resection: wedge resection or segmentectomy; upper-PF: upper lung field pulmonary fibrosis; VC: vital capacity.
Figure 2:Radiological course of a 68-year-old male patient who underwent right lower lobectomy for stage IA adenocarcinoma. (A) Before surgery, computed tomography showed a pulmonary apical cap (arrow) and a mixed ground-grass opacity in the right lower lobe. A chest radiograph showed a ground-grass opacity in the right middle field of the lung. (B) Postoperative computed tomography 6 months after surgery demonstrated involvement of the pleura (arrow) and subpleural parenchyma (arrowhead) in the right upper lobe and right pleural effusion. (C) At 2 years and 3 months after surgery, a subpleural parenchymal lesion in the right upper lobe appeared to be deteriorated with cystic change and thickened pleural effusion. (D) At 6 years after surgery, the cystic lesion in the right upper lung field was obviously deteriorated with unilateral thoracic deformity.
Figure 3:Radiological course of a 78-year-old male patient who underwent a right upper lobectomy for stage IB adenocarcinoma. (A) Preoperative radiological radiograph showed a small nodule (white arrow) in the right middle lung field, and chest computed tomography demonstrated a pulmonary apical cap (arrowhead) and a nodule (black arrow) in the right upper lobe. (B) Postoperative computed tomography at 6 months after surgery showed no abnormal shadows except for a small amount of pleural effusion (arrow) on the operated side. (C) At 4 years and 8 months after surgery, pleural thickening and subpleural fibrosis lesion emerged in the right upper lung field with unilateral thoracic deformity and thickened pleural effusion.